New research evaluates clinical trials investigating post-acute COVID-19 syndrome treatment

In a recent article published in Clinical Microbiology and Infection, researchers reviewed all registered trials currently investigating potential treatment options for post-acute coronavirus disease 2019 (COVID-19) syndrome (PACS).

The NIH poured $1 billion into long Covid research, with little to show for it

A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study - The Lancet Respiratory Medicine

Study identifies risk factors for long-haul COVID disease in adults - Mayo Clinic News Network

Two Years into the COVID-19 Pandemic: Lessons Learned

Post-acute COVID-19 syndrome and kidney diseases: what do we know?

Randomized Trial of Anticoagulation Strategies for Noncritically Ill Patients Hospitalized With COVID-19

Frontiers Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms

What We Know about Long COVID—and What We Don't, The Brink

VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19

Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial - eClinicalMedicine